Axovant Sciences Ltd. (NASDAQ:AXON) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Wednesday.

Several other research analysts have also recently weighed in on the company. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Axovant Sciences in a report on Sunday, November 12th. Piper Jaffray Companies restated a “hold” rating on shares of Axovant Sciences in a report on Friday, November 10th. Zacks Investment Research cut Axovant Sciences from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. Chardan Capital restated a “sell” rating and set a $3.00 target price on shares of Axovant Sciences in a report on Friday, November 3rd. Finally, Robert W. Baird restated a “hold” rating and set a $6.00 target price on shares of Axovant Sciences in a report on Wednesday, November 1st. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the stock. Axovant Sciences currently has a consensus rating of “Hold” and a consensus price target of $14.13.

Shares of Axovant Sciences (AXON) traded up $0.19 during trading on Wednesday, hitting $5.65. The stock had a trading volume of 1,010,556 shares, compared to its average volume of 1,029,573. Axovant Sciences has a fifty-two week low of $4.60 and a fifty-two week high of $27.98. The company has a debt-to-equity ratio of 0.34, a quick ratio of 5.94 and a current ratio of 5.94.

ILLEGAL ACTIVITY WARNING: “Axovant Sciences Ltd. (AXON) Raised to “Hold” at BidaskClub” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/22/axovant-sciences-ltd-axon-raised-to-hold-at-bidaskclub.html.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AXON. FMR LLC lifted its holdings in Axovant Sciences by 968.5% in the second quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock valued at $167,794,000 after acquiring an additional 6,558,462 shares during the last quarter. Janus Henderson Group PLC acquired a new position in Axovant Sciences in the second quarter valued at approximately $47,854,000. OxFORD Asset Management LLP lifted its holdings in Axovant Sciences by 842.1% in the third quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock valued at $5,838,000 after acquiring an additional 777,505 shares during the last quarter. Capital Research Global Investors lifted its holdings in Axovant Sciences by 21.8% in the second quarter. Capital Research Global Investors now owns 3,453,800 shares of the biotechnology company’s stock valued at $80,094,000 after acquiring an additional 619,226 shares during the last quarter. Finally, Eagle Asset Management Inc. acquired a new position in Axovant Sciences in the third quarter valued at approximately $4,471,000. Hedge funds and other institutional investors own 99.69% of the company’s stock.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.